Bortezomib, Mitoxantrone Hydrochloride Liposome, and Dexamethasone for Relapsed/Refractory Multiple Myeloma: A Multi‐Center, Open‐Label Phase I Trial
Cancer Medicine · 2025
DOI: 10.1002/cam4.70890 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Cancer Medicine, 2025. Verfasst von Ya-Lan Zhou und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Bortezomib, Dexamethasone, Mitoxantrone. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co. Ltd., National Natural Science Foundation of China.
Abstract (Originalsprache)
Backgrounds Mitoxantrone hydrochloride liposome (Lipo‐MIT) has shown clinical benefits in various tumors. However, there is no prospective study evaluating its effectiveness and safety in relapsed/refractory multiple myeloma (RRMM). A phase I trial of bortezomib, Lipo‐MIT, and dexamethasone (VMitD) with the primary endpoints being safety and efficacy was performed.
Methods
Twenty subjects were enrolled this study, and the dose of Lipo‐MIT was designed to be 12, 16, and 20 mg/m 2 at Day 1 combined with bortezomib and dexamethasone.
Results
The most common grade 3/4 non‐hematologic adverse event was pneumonia (20%). The most frequently observed grade 3/4 hematologic toxicity included thrombocytopenia (70%), neutropenia (55%), lymphopenia (30%), and anemia (10%). Fifteen subjects received at least one efficacy evaluation, including 60% (9/15) with a very good partial response (VGPR) or better, resulting in an overall response rate (ORR) of 86.7% (13/15).
Conclusions
This is the first report about the novel triplet regimen VMitD, including Lipo‐MIT for RRMM, which was well tolerated and demonstrated efficacy. Further studies are required to assess the outcomes more accurately and to evaluate its effectiveness in comparison to other salvage regimens containing proteasome inhibitors and anthracyclines. Trial Registration: ClinicalTrials.gov identifier: NCT05052970
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.
- Department of Hematology, The Third Hospital of Hebei Medical University, Hebei, China.
- Department of Hematology, The Second Affiliated Hospital of Harbin Medical University, Heilongjiang, China.
- Department of Hematology, Beijing Jishuitan Hospital, Capital Medical University, Beijing, China.
- Department of Hematology, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Henan, China.
- Department of Hematology, Affiliated Hospital of Inner Mongolia Medical University, Inner Mongolia, China.
ORCID-Profile: Ya-Lan Zhou, Li Bao, Wen-Ming Chen
Förderung
- CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co. Ltd.
- National Natural Science Foundation of China
Zitieren
APA
Zhou, Y. L., Zhang, J. Q., Wang, W., Bao, L., Fang, B. J., Gao, D., Su, L. P., Chen, W. M., & Yang, G. Z. (2025). Bortezomib, Mitoxantrone Hydrochloride Liposome, and Dexamethasone for Relapsed/Refractory Multiple Myeloma: A Multi‐Center, Open‐Label Phase I Trial. Cancer Medicine. https://doi.org/10.1002/cam4.70890
Vancouver
Zhou YL, Zhang JQ, Wang W, Bao L, Fang BJ, Gao D, et al. Bortezomib, Mitoxantrone Hydrochloride Liposome, and Dexamethasone for Relapsed/Refractory Multiple Myeloma: A Multi‐Center, Open‐Label Phase I Trial. Cancer Medicine. 2025. doi:10.1002/cam4.70890
BibTeX
@article{Zhou2025,
author = {Zhou, Ya-Lan and Zhang, Jin-Qiao and Wang, Wei and Bao, Li and Fang, Bai-Jun and Gao, Da and Su, Li-Ping and Chen, Wen-Ming and Yang, Guang-Zhong},
title = {Bortezomib, Mitoxantrone Hydrochloride Liposome, and Dexamethasone for Relapsed/Refractory Multiple Myeloma: A Multi‐Center, Open‐Label Phase I Trial},
journal = {Cancer Medicine},
year = {2025},
doi = {10.1002/cam4.70890}
}
EUVIMED